<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00494494</url>
  </required_header>
  <id_info>
    <org_study_id>05-3115</org_study_id>
    <nct_id>NCT00494494</nct_id>
  </id_info>
  <brief_title>Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery</brief_title>
  <official_title>Effect of Nepafenac on Post-operative Cystoid Macular Edema Following Uncomplicated Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Research to Prevent Blindness</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: Study the effect of nepafenac ophthalmic suspension 0.1% to prevent post-operative
      cystoid macular edema following uncomplicated cataract surgery

      Participants: Patients having cataract surgery at UNC who meet eligibility criteria

      Procedures (methods): Patients will have pre and post-operative vision measured and optical
      coherence tomography (OCT) testing, also cataract density and intraoperative
      phacoemulsification parameters including ultrasound power and ultrasound time will be
      measured. Patients will be randomized into two groups. Group 1 will be treated with standard
      post-operative cataract management. Group 2 will be treated with standard post-operative
      cataract management plus topical nepafenac for one month. Post-operative macular thickness
      will be studied by analyzing the visual acuity and OCT measurements at two months post
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We plan to enroll 80 patients in this prospective randomized clinical trial. Eligible
      patients will be randomized into two groups. All patients will have pre-operative Early
      Treatment of Diabetic Retinopathy Study (ETDRS) vision measured and pre-operative OCT
      (Humphrey-Zeiss Medical Systems, San Leandro, CA) in both eyes. OCT measurements will include
      total macular volume, central foveal thickness, and average macular thickness.
      Pre-operatively, all cataracts will be graded using the LOCS III classification system.10
      Group 1 will receive pre-operative topical nepafenac to maintain intra-operative pupillary
      dilation which is standard care for cataract surgery. Following surgery Group 1 will be
      treated with standard post operative cataract treatment, including a topical antibiotic and a
      topical corticosteroid. Group 2 will also receive pre-operative topical nepafenac to maintain
      intra-operative pupillary dilation. Following surgery patients in Group 2 will be treated
      with topical nepafenac, a topical antibiotic, and a topical corticosteroid. Group 2 will be
      given the 3ml bottle of nepafenac to take home and instructed to use it three times per day
      for one month. Intra-operative surgical parameters including ultrasound time and average
      percent phacoemulsification power will be recorded for all surgeries. All patients will be
      seen on post-operative day one, one week, one month, and two months. At the two month visit,
      best corrected ETDRS vision and OCT will be repeated in both eyes. The two month visual
      acuity and post-operative OCT will be analyzed to evaluate the effect of nepafenac on CME
      following cataract surgery. Wilcoxon signed rank test will be used to compare pre-operative
      and post-operative differences between visual acuity and OCT measurements. The Spearman
      correlation will be used to compare the variables in the study including cataract density,
      ultrasound time, average percent phacoemulsification power, and OCT measurements.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central Macular Thickness (Difference in Mean Pre-post Changes by the Two Treatment Groups)</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>The endpoints of the study were change in macular thickness measured by OCT in the central 1mm diameter centred on the fovea (central macular thickness)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre-operative Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>baseline</time_frame>
    <description>Patients were instructed to read letters on the EDTRS visual acuity chart. The mean and standard deviation for each group was measured. Letters range from 0 (20/2000) to 110 (20/12.5), with the higher number signaling better visual acuity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Foveal Thickness</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>difference in mean pre-post changes by the two treatment groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Macular Volume (Difference in Mean Pre-post Changes by the Two Treatment Groups)</measure>
    <time_frame>baseline and 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-operative Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>The patients were again instructed to read letters on the ETDRS chart 8 weeks post-surgery. The mean and standard deviation for each group was recorded. Letters range from 0 (20/2000) to 110 (20/12.5), with the higher number signaling better visual acuity.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Cystoid Macular Edema</condition>
  <arm_group>
    <arm_group_label>Standard Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>topical antibiotic for 10 days and a topical corticosteroid for 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nepafenac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop per study eye three times per day for 30 days in addition to standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Care</intervention_name>
    <description>topical antibiotic for 10 days plus topical corticosteroids for 1 month</description>
    <arm_group_label>Standard Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nepafenac</intervention_name>
    <description>liquid drops, administered three times per day for 1 month in addition to standard care use of topical antibiotic and topical corticosteroid</description>
    <arm_group_label>Nepafenac</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  over age 50

          -  having cataract surgery at UNC

        Exclusion Criteria:

          -  medically controlled diabetes

          -  history of intraocular surgery

          -  abnormal pre-op optical coherence tomography scan

          -  history of ocular inflammation

          -  have age related macular degeneration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth C Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2007</study_first_submitted>
  <study_first_submitted_qc>June 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2007</study_first_posted>
  <results_first_submitted>April 11, 2011</results_first_submitted>
  <results_first_submitted_qc>June 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 12, 2011</results_first_posted>
  <last_update_submitted>June 13, 2011</last_update_submitted>
  <last_update_submitted_qc>June 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kenneth Cohen, MD</name_title>
    <organization>UNC Chapel Hill</organization>
  </responsible_party>
  <keyword>cystoid macular edema</keyword>
  <keyword>cataract</keyword>
  <keyword>nonsteroidal antiinflammatory drugs</keyword>
  <keyword>optical coherence tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Nepafenac</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Treatment</title>
          <description>These subjects only received the standard of care for post-operative cataract, which consists of a topical antibiotic and a topical corticosteroid.</description>
        </group>
        <group group_id="P2">
          <title>Nepafenac</title>
          <description>1 drop per study eye three times per day for 30 days plus standard care</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Treatment</title>
          <description>These subjects only received the standard of care for post-operative cataract, which consists of a topical antibiotic and a topical corticosteroid.</description>
        </group>
        <group group_id="B2">
          <title>Nepafenac</title>
          <description>1 drop per study eye three times per day for 30 days plus standard care</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.33" spread="8.04"/>
                    <measurement group_id="B2" value="73.95" spread="8.99"/>
                    <measurement group_id="B3" value="72.14" spread="8.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Central Macular Thickness (Difference in Mean Pre-post Changes by the Two Treatment Groups)</title>
        <description>The endpoints of the study were change in macular thickness measured by OCT in the central 1mm diameter centred on the fovea (central macular thickness)</description>
        <time_frame>baseline and 8 weeks</time_frame>
        <population>Three subjects in the treatment group and two subjects in the control group had unreliable preoperative OCT scans because of dense posterior subcapsular cataracts. These subjects were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>These subjects only received the standard of care for post-operative cataract, which consists of a topical antibiotic and a topical corticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Nepafenac</title>
            <description>1 drop per study eye three times per day for 30 days plus standard care</description>
          </group>
        </group_list>
        <measure>
          <title>Central Macular Thickness (Difference in Mean Pre-post Changes by the Two Treatment Groups)</title>
          <description>The endpoints of the study were change in macular thickness measured by OCT in the central 1mm diameter centred on the fovea (central macular thickness)</description>
          <population>Three subjects in the treatment group and two subjects in the control group had unreliable preoperative OCT scans because of dense posterior subcapsular cataracts. These subjects were excluded from the analysis.</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.78" lower_limit="-10.12" upper_limit="15.68"/>
                    <measurement group_id="O2" value="5.6" lower_limit="-8.2" upper_limit="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no correlation between the 2 groups. Standard methods were used for power calculation to determine the sample size needed to have 0.90 power for the comparison between two groups at the two-sided significance of 0.05.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Our estimate of a clinically relevant increase is 25 microns. With these specifications, the sample size that is required to have 0.90 power for the comparison between two groups at the two-sided 0.05 significance level is about 10 per group.</non_inferiority_desc>
            <p_value>0.7029</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.82</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>13.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.27</ci_lower_limit>
            <ci_upper_limit>8.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pre-operative Best Corrected Visual Acuity (BCVA)</title>
        <description>Patients were instructed to read letters on the EDTRS visual acuity chart. The mean and standard deviation for each group was measured. Letters range from 0 (20/2000) to 110 (20/12.5), with the higher number signaling better visual acuity.</description>
        <time_frame>baseline</time_frame>
        <population>The analysis was per protocol. At baseline, everybody was given a Best Corrected Visual Acuity Assessment (BCVA).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>These subjects only received the standard of care for post-operative cataract, which consists of a topical antibiotic and a topical corticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Nepafenac</title>
            <description>1 drop per study eye three times per day for 30 days plus standard care</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-operative Best Corrected Visual Acuity (BCVA)</title>
          <description>Patients were instructed to read letters on the EDTRS visual acuity chart. The mean and standard deviation for each group was measured. Letters range from 0 (20/2000) to 110 (20/12.5), with the higher number signaling better visual acuity.</description>
          <population>The analysis was per protocol. At baseline, everybody was given a Best Corrected Visual Acuity Assessment (BCVA).</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.48" spread="9.83"/>
                    <measurement group_id="O2" value="40.49" spread="9.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1937</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.01</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>9.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.41</ci_lower_limit>
            <ci_upper_limit>6.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Foveal Thickness</title>
        <description>difference in mean pre-post changes by the two treatment groups</description>
        <time_frame>baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>These subjects only received the standard of care for post-operative cataract, which consists of a topical antibiotic and a topical corticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Nepafenac</title>
            <description>1 drop per study eye three times per day for 30 days plus standard care</description>
          </group>
        </group_list>
        <measure>
          <title>Foveal Thickness</title>
          <description>difference in mean pre-post changes by the two treatment groups</description>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-25.4" upper_limit="21.4"/>
                    <measurement group_id="O2" value="4.7" lower_limit="-14.9" upper_limit="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5066</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>6.70</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>19.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.12</ci_lower_limit>
            <ci_upper_limit>16.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Macular Volume (Difference in Mean Pre-post Changes by the Two Treatment Groups)</title>
        <time_frame>baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>These subjects only received the standard of care for post-operative cataract, which consists of a topical antibiotic and a topical corticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Nepafenac</title>
            <description>1 drop per study eye three times per day for 30 days plus standard care</description>
          </group>
        </group_list>
        <measure>
          <title>Macular Volume (Difference in Mean Pre-post Changes by the Two Treatment Groups)</title>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="-0.46" upper_limit="0.56"/>
                    <measurement group_id="O2" value="0.10" lower_limit="-0.11" upper_limit="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5099</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.05</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.227</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Post-operative Best Corrected Visual Acuity (BCVA)</title>
        <description>The patients were again instructed to read letters on the ETDRS chart 8 weeks post-surgery. The mean and standard deviation for each group was recorded. Letters range from 0 (20/2000) to 110 (20/12.5), with the higher number signaling better visual acuity.</description>
        <time_frame>baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment</title>
            <description>These subjects only received the standard of care for post-operative cataract, which consists of a topical antibiotic and a topical corticosteroid.</description>
          </group>
          <group group_id="O2">
            <title>Nepafenac</title>
            <description>1 drop per study eye three times per day for 30 days plus standard care</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Best Corrected Visual Acuity (BCVA)</title>
          <description>The patients were again instructed to read letters on the ETDRS chart 8 weeks post-surgery. The mean and standard deviation for each group was recorded. Letters range from 0 (20/2000) to 110 (20/12.5), with the higher number signaling better visual acuity.</description>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.46" lower_limit="39" upper_limit="67"/>
                    <measurement group_id="O2" value="55.49" lower_limit="44" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5005</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.03</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.49</ci_lower_limit>
            <ci_upper_limit>3.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and/or other adverse Events were not collected for this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard Treatment</title>
          <description>These subjects only received the standard of care for post-operative cataract, which consists of a topical antibiotic and a topical corticosteroid.</description>
        </group>
        <group group_id="E2">
          <title>Nepafenac</title>
          <description>1 drop per study eye three times per day for 30 days plus standard care</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Although the peak incidence of CME is said to be at 4â€“12 weeks after surgery, we may have missed the time course for detecting the maximum increased OCT measured macular thickness.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kennth L. Cohen, MD</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>919 843-0292</phone>
      <email>klc@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

